Concomitant Inhibition of FASN and SREBP Provides a Promising Therapy for CTCL

Concomitant Inhibition of FASN and SREBP Provides a Promising Therapy for CTCL

Cutaneous T cell lymphoma (CTCL) is a group of non-Hodgkin’s primary cutaneous T cell lymphomas, with Mycosis Fungoides and Sézary syndrome (SS) being the two most common subtypes. Fatty acid synthase (FASN) is a crucial enzyme that catalyses the biosynthesis of fatty acids, which has been reported...

Full description

Bibliographic Details
Main Authors: Cheng Chi, Lisa Harth, Marina Ramírez Galera, Marina Passos Torrealba, Chella Krishna Vadivel, Carsten Geisler, Charlotte Menné Bonefeld, Pia Rude Nielsen, Michael Bzorek, Jürgen C. Becker, Lise Mette Rahbek Gjerdrum, Niels Ødum, Anders Woetmann
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Cancers
Subjects:
CTCL
FASN
SREBP
cancer therapy
Online Access:https://www.mdpi.com/2072-6694/14/18/4491

Internet

https://www.mdpi.com/2072-6694/14/18/4491

Similar Items